Dr. Lal Pathlabs Q2 Results Review - Inline; Volume Growth Still Lackluster: Yes Securities

Yes Securities Report

Dr. Lal Pathlabs Ltd. reported largely in line quarter as sample growth yet again outpaced volume expansion. Swasthfit share continues to rise YoY which is driving large part of realization improvement.

Margin strength is consistently evident even as management alluded to higher opex in H2 leading to lower projected margin for the second half.

With no visible price hike in FY25, expect bulk of the per patient realization to come from mix change and small contribution from geography/product mix.

We marginally tweak our realization and 50 basis points higher gross margin resulting in 3-4% change to FY25 and FY26 estimates.

Retain 'Sell' based on unchanged 40 times as reckon there is unlikely to be a revenue surprise in the near term that precludes meaningful upgrades.

Click on the attachment to read the full report:

DISCLAIMER

This report is authored by an external party. NDTV Profit does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of NDTV Profit.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.